Navigation Links
Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo™ Bio-engineered Sirolimus Eluting Stent
Date:9/24/2010

WASHINGTON, Sept. 24 /PRNewswire/ -- OrbusNeich today announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington the completion of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) with 183 patients included at sites in Asia, Australia, Europe and South America.

"Completion of enrollment of this study represents a significant milestone as we look to validate the potential for the Combo Stent in a clinical setting," said Al Novak, Chairman and CEO of OrbusNeich.

The primary objective of the prospective, randomized, multicenter study, called REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt), is to demonstrate safety and effectiveness of the Combo Stent compared to the TAXUS® Liberte® paclitaxel-eluting stent in patients with symptomatic, ischemic heart disease due to a stenotic lesion located in a native coronary artery. This objective will be measured in patients by a comparison of in-stent late lumen loss at nine months post-procedure.

Michael Haude, M.D., director of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, and one of the trial's principal investigators, added, "The Combo Stent has the potential to bring a unique treatment option to physicians by combining the proven Genous endothelial progenitor cell capture technology with a low dose sirolimus elution. Because the pre-clinical data demonstrate lower neointimal hyperplasia and improved endothelial coverage, we look forward to obtaining clinical confirmation of the results."

Secondary endpoints include all-cause and cardiac mortality, myocardial infarction, Major Adverse Cardiac Event (MACE) and stent thrombosis rates at 30 days, nine months and one through five years, as well as clinically driven Target Lesion Revascularization (TLR), Target Ves
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015  Hologic, Inc. (NASDAQ: ... cancer screening study i published on-line this ... journal of the American Cancer Society. ... the University of Pittsburgh Medical Center, supports current consensus guidelines ... that women 30-65 years of age be co-tested ...
(Date:4/16/2015)... April 16, 2015 Mallinckrodt plc (NYSE: ... today announced that it has completed its acquisition ... approximately $2.3 billion. The Ikaria acquisition extends Mallinckrodt,s ... reach into neonatal critical care with INOMAX ® ... for a highly vulnerable patient population. It also ...
(Date:4/16/2015)... , April 16, 2015  Rosewind Corporation (OTCMKTS: ... reverse merger with a newly formed specialty healthcare ... focus on addressing urological disorders. The merged company, ... Inc., has commenced operations and incorporates the pipeline ... The Company,s strategy is to build a late-stage ...
Breaking Medicine Technology:Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 2Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 3Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 4Mallinckrodt Completes Acquisition Of Ikaria 2Mallinckrodt Completes Acquisition Of Ikaria 3Mallinckrodt Completes Acquisition Of Ikaria 4Mallinckrodt Completes Acquisition Of Ikaria 5Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 2Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 3
... Fla., May 26, 2011 Tigris Pharmaceuticals, Inc., today ... Phase 2 clinical trial of AFP-464 (aminoflavone prodrug) with ... cancer patients. Molecular profiling will be used to pre-screen ... which has shown to predict sensitivity to ...
... 26, 2011 Medical Affairs serves as the linchpin for ... a successful market entry of a new product. ... trial strategy & planning, and publication strategy & planning, are ... the activities where organizations turn to Medical Affairs to play ...
Cached Medicine Technology:Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients 2Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients 3Medical Affairs Role in New Product Planning Detailed in Best Practices, LLC Report 2
(Date:4/18/2015)... “ ArcAngel ” was featured on NewsWatch as part of ... and coolest applications on the market for iOS, ... technology expert, conducted the app review and shared with viewers ... a turbulent world, people may find themselves in dangerous situations ... first move, but some situations can be avoided if there ...
(Date:4/17/2015)... Rosetta Radiology is proud to now offer ... of diagnostic imaging services. This solidifies them as a ... East Side of Manhattan. , The new imaging equipment ... of PET-CT, combined with Rosetta’s state of the art ... with patients through several stages of the cancer care ...
(Date:4/17/2015)... have seen healing, a lot of healing, and a lot ... Kafader of Friendship Village. “People have found purpose. ... have created beautiful pieces of art.” For the past eight ... was launched to benefit residents of the retirement community. , ... Institute in Chicago, worked as an intern at Friendship Village, ...
(Date:4/17/2015)... Rapids, MI (PRWEB) April 17, 2015 Enthusiasts ... CRUSH Grand Rapids, Saturday, April 25, 2015. The event will ... Reserve Wine & Food (201 Monroe Ave NW, Grand Rapids, ... from around the West Michigan area. Patrons are encouraged to ... of elegance and fun. , This year’s event will feature ...
(Date:4/17/2015)... Baptist Health and The University of Texas ... designed to transform oncology care in northeast Florida and ... create a joint cancer program to enhance patient access ... MD Anderson Cancer Center is anticipated to open in ... highly coordinated, multidisciplinary cancer care for adults in the ...
Breaking Medicine News(10 mins):Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:Healing At Friendship Village Due To Art Therapy 2Health News:Children’s Leukemia Foundation of Michigan Presents 3rd Annual CRUSH Grand Rapids 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3
... up nationwide installation service for its smartTOUCH(R),product line, ... (OTC,Bulletin Board: BMRX) today announced that it has ... national handyman service, Mr.,Handyman, to provide its customers ... products that,include garage door openers, door locks, thermostats, ...
... Non-systemic and Non-invasive Treatment Cleared for,Patients Who Have ... Pa., Oct. 8 Neuronetics, Inc., a,privately-held medical ... of,neuromodulation, announced today that the U.S. Food and ... Magnetic Stimulation),Therapy system for the treatment of depression. ...
... 8 ILC Dover (http://www.ilcdover.com ),the company ... a premium line of aesthetically pleasing head covers ... product is the direct result,of feedback from healthcare ... less intimidating and more "patient friendly"., (Photo: ...
... ,Tis the season to be jolly, but all,the money ... have you,feeling less than merry. Don,t let yourself fall ... sense of obligation. Take the following,simple measures to prevent ... Family Therapists (CAMFT) http://www.camft.org :, -- Make ...
... Canadian Annual Meeting (November 5-7; Ottawa, Ontario, Canada) to ... the pharmaceutical industry, health academia, and the health care ... ... Horsham, PA (PRWEB) October 8, 2008 -- The http://www.diahome.org/ ...
... extension of its existing strategic alliance with Nano-Terra, Inc., a leading ... ... Wire EON) October 7, 2008 -- The original agreement between ... products and solutions based on Merck,s materials. , , , After ...
Cached Medicine News:Health News:bioMETRX Teams Up With Mr. Handyman 2Health News:bioMETRX Teams Up With Mr. Handyman 3Health News:FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression 2Health News:FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression 3Health News:FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression 4Health News:FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression 5Health News:ILC Dover Introduces 'Patient Friendly' Respiratory Protection for Health Care Market 2Health News:Holiday Gift Giving: How You and Your Budget can Survive the Season 2Health News:DIA 6th Canadian Annual Meeting Benefit and Risk Management: An Evolution in Progress 2Health News: Merck KGaA and Nano-Terra Announce Extension of Nanotechnology Solutions Alliance 2Health News: Merck KGaA and Nano-Terra Announce Extension of Nanotechnology Solutions Alliance 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: